Project Grant R21EB035772
- Biomesense Inc. received a $883,212 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences to develop a novel biosensor to accelerate investigations of the gut microbiome. The grant will support validating the microbial lysis and DNA isolation functions of a prototype biosensor over a 6-month period ending December 31, 2021. The biosensor is intended to enable dense, time-longitudinal sampling of participants' gut microbiomes in their...
- This National Science Foundation (NSF) Project Grant, awarded under the Computer and Information Science and Engineering (CISE) program (CFDA 47.070), provides $168,690 to the Florida Institute of Technology Inc. (Florida TECH) to develop a theragnostic (therapeutic + diagnostic) system for inflammatory bowel diseases (IBD). The project aims to model the complex interplay of host, microbial, and environmental factors that trigger IBD using data science, and then leverage synthetic biology and...
- This $202,728 federal Project Grant awarded by the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program funds a collaborative research project to develop a theragnostic (therapeutic and diagnostic) system for inflammatory bowel diseases (IBD). The project aims to integrate data science, synthetic biology, and additive manufacturing to model the complex interplay of host, microbial, and environmental factors in IBD, and develop an engineered...
- This four-year, $924,987 project grant from the National Science Foundation's Division of Integrative Organismal Systems and Directorate for Biological Sciences will fund research into the role of extracellular RNA (exRNA) in intercellular and interkingdom communication. Specifically, the collaborative project between seven laboratories will examine the hypothesis that RNA secreted by host cells plays a key role in maintaining microbiome and overall health through cell-to-cell communication...
- This National Science Foundation (NSF) Biological Sciences grant award provides $2,225,964 to the Georgia Tech Research Corporation (Georgia Tech) to develop a novel biosensing platform called "protocell communities" that can be used for rapid, low-cost medical diagnostics. The project aims to create a tool that can diagnose medical conditions by detecting and integrating multiple indicator molecules, addressing limitations of single-analyte diagnostics. The protocell technology uses...
- This National Science Foundation (NSF) Computer and Information Science and Engineering (CISE) Federal Grant Program (CFDA 47.070) award of $1,200,000 provides funding to the University of California, Berkeley from October 1, 2024 to September 30, 2028 to develop innovative sensing technologies that integrate DNA nanotechnology and CMOS electronics for next-generation diagnostics. The key objectives of this project grant are to: (1) develop molecular engineering techniques using DNA origami...
- Biomesense Inc. received a $255,658 National Science Foundation SBIR Phase I Project Grant to develop a novel biosensor to accelerate investigations of COVID-19 and the gut microbiome. Funded under the NSF Engineering program (CFDA 47.041), this six-month award beginning January 15, 2021 supports the company's work to design a portable, low-cost biosensor device capable of rapidly detecting SARS-CoV-2 and analyzing gut microbiome composition directly from patient samples. The NSF Directorate for...
- This $406,167 Project Grant, awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports a five-year research initiative at the University of Vermont focused on developing computational models to predict microbiome dynamics. The award, effective May 15, 2026, through March 31, 2031, funds the creation of multi-scale mathematical and computational frameworks that integrate metagenomic sequencing data...
- The National Institute of General Medical Sciences (NIGMS) awarded a $1,338,750 Project Grant to Yale University to conduct research on how gut bacteria can influence host feeding behavior and microbiome assembly using the roundworm Caenorhabditis elegans as a model system. The project aims to develop tools and assays to study the molecular mechanisms by which gut microbes can manipulate host feeding decisions, with the goal of gaining insights that may apply to other host-microbe systems. Key...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $426,425 to Baylor College of Medicine to conduct a pilot study examining the relationship between gut microbiome composition, metabolic dysfunction-associated steatotic liver disease (MASLD), and hepatocellular carcinoma (HCC). The key objectives of this 2-year study are to: 1) characterize baseline gut microbiome diversity associated with MASLD with and without HCC, 2)...
DNA RECORDER: LIVING BIOSENSOR FOR ARBITRARY DNA - PROJECT SUMMARY RECENT DECADES HAVE REVEALED THE PROFOUND IMPACTS THAT GUT MICROBIOTA HAVE ON HUMAN HEALTH. FAR BEYOND BEING SIMPLY PATHOGENIC VS BENIGN, GUT MICROBES IMPACT A VARIETY OF HEALTH AND DISEASE STATES, INCLUDING METABOLIC, DIGESTIVE, AND MENTAL HEALTH, AS WELL AS PROPENSITY TO CANCER. ADDING TO THE COMPLEXITY, GUT MICROBES CAN INFLUENCE THE METABOLISM, AND THEREBY ACTION, OF DRUGS DEVELOPED TO PROMOTE HEALTH AND TREAT DISEASE. THIS SUGGESTS THAT MANY CONDITIONS WOULD BENEFIT FROM A MORE PERSONALIZED TREATMENT PLAN THAT TAKES INDIVIDUAL GUT MICROBIOTA INTO ACCOUNT. STRATIFYING BY MICROBIAL PROFILE MAY ALSO BENEFIT DRUG DEVELOPMENT, BY REMOVING A CONFOUNDING VARIABLE IN CLINICAL TRIALS. THE CURRENT STANDARD METHOD OF MEASURING THE GUT MICROBIOTA IS VIA FECAL SAMPLES. HOWEVER, WHILE CONVENIENT, INEXPENSIVE, AND NON-INVASIVE, THESE SAMPLES DO NOT ACCURATELY REFLECT THE DETAILS OF GUT COMMUNITIES. UP TO A THIRD OF INTESTINAL MICROBES CAN BE EFFECTIVELY ABSENT FROM FECAL SAMPLES, WHICH ALSO FAIL TO PRESERVE INFORMATION ABOUT SPATIAL STRUCTURE. THEREFORE, NEW MEASUREMENT TECHNIQUES ARE NEEDED TO MORE ACCURATELY PROFILE GUT MICROBIOTA. HERE, WE WILL DEVELOP AN INNOVATIVE APPROACH THAT USES LIVING BIOSENSORS TO RECORD EXTRACELLULAR DNA AS THEY TRAVERSE THE GUT, PRESERVING A RECORD OF THE INTERNAL MICROBIAL COMPOSITION AND SPATIAL STRUCTURE. THIS STRATEGY RELIES ON NATURALLY COMPETENT BACTERIA, WHICH WE RECENTLY USED TO DETECT DNA RELEASED FROM COLORECTAL TUMORS IN VIVO. THE FIRST TWO AIMS WILL DEVELOP COMPLEMENTARY STRATEGIES TO STORE EXTRACELLULAR DNA, AND THE THIRD WILL DEMONSTRATE THEM IN MICE. IN AIM 1, WE WILL STORE SNIPPETS OF ENVIRONMENTAL DNA IN CRISPR ARRAYS FOR LATER READOUT. THIS AIM INCLUDES THE ENDOGENOUS CRISPR-CAS SYSTEM, AS WELL AS ALTERNATIVE SYSTEMS THAT MAY BE BETTER SUITED FOR THE TARGET DNA. IN AIM 2, WE WILL TEST THE HYPOTHESIS THAT ENVIRONMENTAL DNA CAN INSTEAD BE STORED BY CASPOSASES, WHICH COULD ALLOW STORAGE OF LONGER SNIPPETS. THESE TWO AIMS SERVE AS ALTERNATIVE APPROACHES FOR EACH OTHER, AND BOTH APPROACHES WILL ALSO ENCODE BIO-SPATIAL INFORMATION IN THE ORDER OF RECORDED DNA SEQUENCES. IN AIM 3, WE WILL VALIDATE THE GUT DNA RECORDER IN VIVO USING MOUSE MODELS OF DYSBIOSIS. THIS WORK WILL DEVELOP HIGHLY INNOVATIVE APPROACHES, WITH RISK APPROPRIATE FOR THIS MECHANISM AND AMELIORATED BY MULTIPLE ALTERNATIVES. THE RESULT OF THIS WORK WILL BE A NOVEL DIAGNOSTIC TECHNIQUE THAT CAN RECORD AND MEASURE THE MICROBIOTA ACROSS THE ENTIRE INTESTINAL TRACT, WITH NO INVASIVE PRODEDURES REQUIRED.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $198.3k | 5/18/26 | ||
| Not listed | $183.0k | 4/17/25 | ||
| Not listed | $183.0k | 7/26/24 | ||
| Not listed | $183.0k | 7/26/24 |